Reaction
Anorectal Disorder reporting signals
As of the last recalculation, Anorectal Disorder appears in 1,981 FAERS reports alongside 33 co-occurring drug terms. The strongest observed disproportionality signal is ATROPINE (PRR 23.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Atropine | 18 | 23.0 | 23.1 |
| Ribavirin | 124 | 21.5 | 21.6 |
| Ado-Trastuzumab Emtansine | 16 | 20.1 | 20.1 |
| Infliximab-Dyyb | 54 | 19.9 | 20.0 |
| Atropine Sulfate | 18 | 17.7 | 17.7 |
| Peginterferon Alfa-2A | 69 | 13.9 | 13.9 |
| Mesalamine | 69 | 13.3 | 13.4 |
| Ciprofloxacin Hydrochloride And Hydrocortisone | 25 | 12.8 | 12.8 |
| Dexamethasone Sodium Phosphate | 12 | 12.5 | 12.5 |
| Fosaprepitant Dimeglumine | 15 | 11.5 | 11.6 |
| Metronidazole | 66 | 11.2 | 11.2 |
| Azathioprine | 84 | 10.4 | 10.4 |
| Cholestyramine | 10 | 8.7 | 8.7 |
| Aprepitant | 15 | 8.6 | 8.6 |
| Rocuronium Bromide | 9 | 8.1 | 8.1 |
| Infliximab | 149 | 7.7 | 7.7 |
| Sunitinib Malate | 28 | 7.6 | 7.6 |
| Vedolizumab | 55 | 6.9 | 6.9 |
| Atovaquone | 5 | 6.5 | 6.5 |
| Doxorubicin Hydrochloride | 20 | 6.5 | 6.5 |
| Chlorthalidone | 7 | 6.4 | 6.4 |
| Teduglutide | 8 | 6.3 | 6.3 |
| Fesoterodine Fumarate | 6 | 5.8 | 5.8 |
| Panitumumab | 8 | 5.4 | 5.4 |
| Irinotecan Hydrochloride | 6 | 4.9 | 4.9 |
| Linaclotide | 10 | 4.0 | 4.0 |
| Ustekinumab | 37 | 3.9 | 3.9 |
| Voclosporin | 3 | 3.6 | 3.6 |
| Vilazodone Hydrochloride | 3 | 3.4 | 3.4 |
| Axitinib | 6 | 3.2 | 3.2 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 3 | 3.1 | 3.1 |
| Orlistat | 6 | 2.4 | 2.4 |
| Nirmatrelvir And Ritonavir | 11 | 2.1 | 2.1 |